Amid efforts to revive operations, Oncoclínicas brought in "specialized labor" when it comes to restructuring.
The company announced on Wednesday evening, February 4th, the hiring of Camille Loyo Faria , former CFO of Americanas, for the position of executive vice president. The news was first reported by the newspaper Folha de S. Paulo .
According to a statement, Faria will be responsible for the strategic leadership of the corporate and business directorates, including areas such as legal and compliance, operations, new business, and human resources.
She will also assume the roles of Chief Financial Officer and Chief Investor Relations Officer, replacing Cristiano Camargo, who is leaving the company. Faria will take office on February 9th.
Bruno Ferrari , CEO of Oncoclínicas, will continue to be responsible for managing the medical and scientific areas and for strategic partnerships with health plan operators "until the board of directors completes its succession process," according to the statement.
Faria arrives at Oncoclínicas after leaving her position as financial director at Americanas in December, remaining as an advisor on matters related to the company's judicial reorganization. She took on the role "in the eye of the storm," shortly after the accounting fraud scandal broke, following a stint at Oi, which was also experiencing difficulties .
During his two years at the retailer, he led, alongside CEO Leonardo Coelho, a profound restructuring , which involved restating the financial statements since 2020 to identify the true financial situation, renegotiating debt, and conducting an operational review, with the sale of assets and a focus on physical retail, with digital as a complement.
Approved by creditors in December 2023, Americanas' judicial reorganization plan was ratified and put into practice in February 2024. At the time, the company had R$ 42 billion in debt to creditors, not including intercompany debt. In the third quarter, gross debt totaled R$ 1.9 billion.
“I assume this position with satisfaction and a high sense of responsibility,” Faria stated in a press release. “My role will be focused on continuing the initiatives already underway, with financial discipline, transparency in our relationship with the market, and execution of the strategic plan, contributing to the sustainability and strengthening of the company.”
At Oncoclínicas, she finds a company that has adopted the motto "back to basics," abandoning plans to expand beyond oncology and incorporate hospitals.
Faria's arrival also represents a loss of power for Ferrari, who is leaving his CEO position, a move orchestrated by the main shareholders, as anticipated by NeoFeed . The expectation is that he will dedicate himself to the board of directors.
Oncoclínicas is evaluating several names to replace him. According to NeoFeed , Spencer Stuart, responsible for the process,is in talks with three executives : Irlau Machado, former CEO of NotreDame Intermédica; Ricardo Bottas, current CFO of Latam Airlines and former CEO of Amil; and Fábio Schvartzman, former CEO of Vale.
Oncoclínicas shares closed the day up 8.09%, at R$ 2.54. Over 12 months, the shares have accumulated a gain of 20.9%, bringing the market value to R$ 2.8 billion.
